How MRI is Helping to De-risk Drug Development

Drug development is a lengthy and costly enterprise and as important it is to take a drug to registration, it is critical to be able to terminate candidates early in the process.  MRI plays a ubiquitous role in supporting go-no go decisions from pre-clinical studies to late phase clinical trials.  MRI provides either direct evidence, through primary biomarkers, or supportive evidence of drug effects.  Its non-invasive nature and radiation-free procedures allows for longitudinal studies to assess disease progression and/or its modulation by intervention.

In this webinar, we reviewed MRI’s role in drug development with specific examples in areas such as neurology, oncology, as well as its future development with the incorporation of advance analytics such as deep learning.